Article
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
Oncotarget - 8 Dec 2015
Cheraghchi-Bashi Azadeh, Parker Christine A, Curry Ed, Salazar Jean-Frederic, Gungor Hatice, Saleem Azeem, Cunnea Paula, Rama Nona, Salinas Cristian, Mills Gordon B, Morris Shannon R, Kumar Rakesh, Gabra Hani, Stronach Euan A
Abstract excerpt
Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795. Proteomic biomarker signatures correlating with effects of GSK2141795 were developed using in vitro and in vivo models, well characterised for related molecular, phenotypic and imaging...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.